SCI时时刷

search
Correction to: First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data
Correction to: First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data
Authors and AffiliationsDepartment of Medicine, Centre Léon-Bérard, Lyon, FranceMaxime Boussageon & Aurélie SwalduzSer...
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine
Biologic drugs have greatly improved treatment outcomes of inflammatory joint diseases, but a substantial proportion of pa...
Rheumatoid Arthritis Treatment Options and Type 2 Diabetes: Unravelling the Association
Rheumatoid Arthritis Treatment Options and Type 2 Diabetes: Unravelling the Association
Multiple lines of evidence have increasingly suggested a pathogenic connection between rheumatoid arthritis (RA) and the m...
Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials
Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials
Oral administration of macromolecules aimed at systemic delivery has been at the forefront of pharmaceutical research for ...
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
Molecular testing is performed upon diagnosis of non-small cell lung cancer (NSCLC) because of the large success of target...
Correction: Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy
Correction: Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy
In Sect. 5.3, there are two occurrences where our submitted version included the text:‘EBV positive (versus negative)’In t...
Extracellular Vesicles Derived from Mesenchymal Stem Cells: A Potential Biodrug for Acute Respiratory Distress Syndrome Treatment
Extracellular Vesicles Derived from Mesenchymal Stem Cells: A Potential Biodrug for Acute Respiratory Distress Syndrome Treatment
Acute respiratory distress syndrome (ARDS) is a severe respiratory disease associated with high morbidity and mortality in...
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis
Systemic amyloidoses are characterized by the unrelenting deposition of autologous proteins as highly ordered fibrils in t...
Teserpaturev/G47Δ: First Approval
Teserpaturev/G47Δ: First Approval
Teserpaturev/G47Δ (Delytact®) is a third-generation (triple-mutated) recombinant oncolytic herpes simplex virus ...
PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras
PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras
In the recent past, proteolysis-targeting chimera (PROTAC) technology has received enormous attention for its ability to o...
Therapeutic siRNA: State-of-the-Art and Future Perspectives
Therapeutic siRNA: State-of-the-Art and Future Perspectives
The highly specific induction of RNA interference-mediated gene knockdown, based on the direct application of small interf...
Real-World Effects of Biologics on Renal Function in Psoriatic Patients: A Retrospective Study
Real-World Effects of Biologics on Renal Function in Psoriatic Patients: A Retrospective Study
Patients with severe psoriasis are prone to deterioration of renal function. Whether biologics with potent anti-inflammato...
Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study
Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study
Biosimilars account for 30–40% of biologic medications dispensed in the United States (US), yet healthcare providers...
The Nocebo Effect in a Non-Medical Switching Program from Originator to Biosimilar Infliximab in Inflammatory Bowel Disease
The Nocebo Effect in a Non-Medical Switching Program from Originator to Biosimilar Infliximab in Inflammatory Bowel Disease
Despite growing awareness of the nocebo effect, few studies have evaluated the nocebo effect using combined assessment of ...
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies
Multiple switches (transitions) between biosimilars of the same reference biologic are now a reality, and they ar...
Plant-Derived Human Vaccines: Recent Developments
Plant-Derived Human Vaccines: Recent Developments
The idea of producing vaccines in plants originated in the late 1980s. Initially, it was contemplated that this notion cou...
The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland
The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland
Biological drugs are generally expensive and produce a continuously growing share of drug costs. Yet they are essential in...
Pharmacists’ Perspectives of Biosimilars: A Systematic Review
Pharmacists’ Perspectives of Biosimilars: A Systematic Review
While biosimilars are less expensive than their originator biologics, various factors are known to impede their uptake in ...
Progress with RNA Interference for the Treatment of Primary Hyperoxaluria
Progress with RNA Interference for the Treatment of Primary Hyperoxaluria
Over the last few years, US Food and Drug Administration-approved drugs using RNA interference have come to the market. Ma...
Interchangeability for Biologics is a Legal Distinction in the USA, Not a Clinical One
Interchangeability for Biologics is a Legal Distinction in the USA, Not a Clinical One
Biologics are increasingly vital medicines that significantly reduce morbidity as well as mortality, yet access continues ...
Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management
Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management
Conventional vaccines have been widely studied, along with their risk of causing allergic reactions. These generally consi...
Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis
Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis
Although most patients with acute pericarditis will recover, a minority will have recurrent, debilitating episodes. In the...